IN8bio's 'off-the-shelf' gamma delta T cells stave off relapse for high-risk leukemia patients in very early data cut
With eyes set on the future of cell therapy, researchers are looking to leverage a growing menagerie of immune cells to engineer a better generation of tumor fighters. One type showing early promise is gamma delta T cells, and now another biotech in that space is trotting out promising — if limited — results.
Three acute myeloid leukemia patients dosed with IN8bio’s off-the-shelf gamma delta T cells remained in remission after a stem cell transplant as long as 20 months after receiving their cells, offering an early vote of confidence for the small biotech’s approach, the company said Thursday.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters